La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ocuphire Pharma Gestion

Gestion contrôle des critères 1/4

Le PDG Ocuphire Pharma's est George Magrath, nommé en Nov2023, a un mandat de moins d'un an. La rémunération annuelle totale est $ 3.15M, composée du salaire de 3% et des bonus 97%, y compris les actions et options de la société. détient directement 0.11% des actions de la société, d'une valeur de € 36.67K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.8 ans et 3.8 ans.

Informations clés

George Magrath

Directeur général

US$3.1m

Rémunération totale

Pourcentage du salaire du PDG	3.0%
Durée du mandat du directeur général	less than a year
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	3.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de George Magrath a-t-elle évolué par rapport aux bénéfices de Ocuphire Pharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

Rémunération vs marché: La rémunération totale de George ($USD 3.15M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 538.74K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de George avec les performances de l'entreprise.

PDG

George Magrath (40 yo)

less than a year

Titularisation

US$3,146,518

Compensation

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
George Magrath	CEO & Director	less than a year	US$3.15m	0.11% € 36.5k
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.41% € 130.9k
Jay Pepose	Chief Medical Advisor & Director	no data	US$662.10k	0.28% € 87.9k
Amy Zaremba Rabourn	Senior Vice President of Finance	no data	US$789.92k	0.029% € 9.4k
Nirav Suresh Jhaveri	Chief Financial Officer	less than a year	pas de données	0.57% € 182.3k
Joseph Schachle	Chief Operating Officer	less than a year	pas de données	0.0076% € 2.4k
Ashwath Jayagopal	Chief Scientific & Development Officer	less than a year	pas de données	0.30% € 95.4k
Bindu Manne	Head of Market Development & Commercialization	2.8yrs	pas de données	pas de données
Erik Sims	Director & Corporate Controller	no data	pas de données	pas de données

0.9yrs

Durée moyenne de l'emploi

46yo

Âge moyen

Gestion expérimentée: L'équipe de direction de R3X1 n'est pas considérée comme expérimentée (ancienneté moyenne 0.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
George Magrath	CEO & Director	less than a year	US$3.15m	0.11% € 36.5k
Jay Pepose	Chief Medical Advisor & Director	3.3yrs	US$662.10k	0.28% € 87.9k
James S. Manuso	Independent Director	3.9yrs	US$154.81k	0.35% € 110.4k
David Boyer	Member of Medical Advisory Board	no data	pas de données	pas de données
Richard Rodgers	Independent Director	3.9yrs	US$1.35m	0.62% € 198.1k
Jeffrey Heier	Member of Medical Advisory Board	no data	pas de données	pas de données
Peter Kaiser	Member of Medical Advisory Board	4.8yrs	pas de données	pas de données
Susan Benton	Independent Director	3.9yrs	US$135.34k	0.38% € 120.1k
Cameron Gallagher	Independent Chairman	3.9yrs	US$174.62k	0.14% € 43.6k
Sean Ainsworth	Lead Independent Director	3.9yrs	US$149.56k	0.18% € 57.4k
David Lally	Member of Medical Advisory Board	2.8yrs	pas de données	pas de données
David Brown	Member of Medical Advisory Board	2.8yrs	pas de données	pas de données

3.9yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de R3X1 sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Ocuphire Pharma Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Recent updates

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.28 loss in 1Q 2023)

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

New minor risk - Profitability

Full year 2023 earnings released: US$0.46 loss per share (vs US$0.90 profit in FY 2022)

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 15%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 15%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Investor sentiment improves as stock rises 16%

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 24%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

Forecast to breakeven in 2022

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics At Annual Macula Society Meeting

Ocuphire Pharma, Inc., Annual General Meeting, Jun 13, 2022

Ocuphire Pharma, Inc. Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Forecast to breakeven in 2024

High number of new directors

No longer forecast to breakeven

Ocuphire Pharma, Inc. Appoints Jay Pepose as Chief Medical Advisor

Ocuphire Pharma, Inc. Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

Ocuphire Pharma, Inc. Provides Update on its APX3330 and Nyxol Clinical Programs

Ocuphire Pharma, Inc. Initiates Enrollment of Nyxol Mira-4 Pediatric Study in Rm Per Agreed Initial Pediatric Study Plan with FDA

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis

Board Member recently bought €51k worth of stock

Insider recently bought €77k worth of stock

Ocuphire Pharma, Inc. Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Ocuphire Pharma, Inc.'s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Ocuphire Pharma, Inc. Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

Ocuphire Pharma, Inc. Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol

Ocuphire Pharma, Inc. Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Ocuphire Pharma, Inc. Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Appoints My Rabourn as the Vice President of Finance and Principal Accounting Officer

Ocuphire Pharma, Inc. Announces Milestones for Patents on Both of its Lead Drug Candidates Nyxol and APX3330

Analyse de la rémunération des PDG

PDG